BRIEF REPORT | doi:10.20944/preprints202008.0519.v1
Subject: Medicine & Pharmacology, Other Keywords: SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome, ARDS, Famotidine, Celecoxib
Online: 24 August 2020 (09:46:15 CEST)
Celecoxib as adjuvant therapy has been shown in a small randomized trial for Covid-19 to prevent clinical deterioration and rapidly improve thoracic computerized axial tomography (CT-chest)1. Multiple descriptive trials of high dose famotidine (both inpatient and outpatient) have demonstrated clinical response2,3,4. We describe the rapid clinical responses after increasing the celecoxib dosage to 400mg bid with high dose famotidine 80mg qid in both a critical inpatient who on baseline required 40 liters per minute high flow nasal insufflation and an outpatient who declined admission but had critical Covid-19 biomarkers.